BioSpace News Archive

Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million.

ImmunityBio, Inc., an immunotherapy company, announced that the U.S. Food and Drug Administration has approved ANKTIVA plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

Affinia Therapeutics announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system such as amyotrophic lateral sclerosis, as well as the Company’s high-yield manufacturing process, will be presented in several oral and poster sessions at the American Society of Gene and Cell Therapy 2024 Annual Meeting, being held May 7-11, 2024 in Baltimore, MD and virtually.

Capsida Biotherapeutics, a leading fully integrated targeted gene therapy company, developing treatments for rare and common diseases across all ages, announced eight presentations – three oral presentations and five poster presentations – at the American Society of Gene & Cell Therapy 2024 Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD and virtually.

ImmPACT Bio USA Inc. (ImmPACT Bio) today announced that it will present new ex vivo preclinical data for ImmPACT Bio’s bispecific Claudin 18.2 (CLDN18.2)/TGF-β chimeric antigen receptor (CAR) T program for the treatment of solid tumors that express CLDN18.2, including gastric and gastroesophageal junction cancer, as part of a poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”) today announced that recently reported twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis will be featured during an oral presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024.

Adicet Bio, Inc. (Nasdaq: ACET) today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD.

Neurogene Inc. (Nasdaq: NGNE) today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that the American Society of Gene & Cell Therapy has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.

TScan Therapeutics, Inc. (Nasdaq: TCRX) today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.